Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1)

Eur J Med Chem. 2020 Jun 1:195:112277. doi: 10.1016/j.ejmech.2020.112277. Epub 2020 Apr 5.

Abstract

Inhibition of MAP3K kinase ASK1 has been an attractive strategy for the treatment of nonalcoholic steatohepatitis and multiple sclerosis, among others. Herein, we reported the discovery of 2-pyridinyl urea-containing compound 14l (YD57) as a potent, small-molecule inhibitor of ASK1. 14l was selective against MAP3K kinases ASK2 and TAK1 (>140-fold), while it also inhibited several cell cycle regulating kinases with IC50 values in a range of 90-400 nM (<20-fold selectivity). As a consequence, 14l had stronger apoptosis induction, more potent G1 cell cycle arrest activities, and lower IC50 value of cell growth inhibition than that of GS4997 in HepG2 cancer cell line. On the other hand, 14l did not inhibit ASK1 and p38 phosphorylation in intact cells. We reason that the multi-target effects of 14l likely neutralized the activities caused by inhibition of cellular ASK1. Future studies of these ASK1 inhibitors should pay close attention to their kinome selectivity profile.

Keywords: ASK1; ASK2; Apoptosis; Cell cycle arrest; Selectivity.

MeSH terms

  • Cell Cycle / drug effects
  • Drug Design*
  • Hep G2 Cells
  • Humans
  • Inhibitory Concentration 50
  • MAP Kinase Kinase Kinase 5 / antagonists & inhibitors*
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / chemistry*
  • Urea / chemistry*
  • Urea / pharmacology*

Substances

  • Protein Kinase Inhibitors
  • Pyridines
  • Urea
  • MAP Kinase Kinase Kinase 5
  • pyridine